Improvements in non-motor and motor fluctuations in parkinson's disease after intermittent apomorphine treatment. 2017

Sevda Erer, and Mehmet Zarifoglu
Department of Neurology, Parkinson's Disease and Movement Disorders Division, Medical School, Uludag University, Bursa, Turkey.

UI MeSH Term Description Entries
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D015259 Dopamine Agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. Dopamine Drugs,Dopamine Effect,Dopamine Effects,Dopaminergic Agents,Dopaminergic Drugs,Dopaminergic Effect,Dopaminergic Effects,Agents, Dopamine,Agents, Dopaminergic,Drugs, Dopamine,Drugs, Dopaminergic,Effect, Dopamine,Effect, Dopaminergic,Effects, Dopamine,Effects, Dopaminergic

Related Publications

Sevda Erer, and Mehmet Zarifoglu
June 1987, Lancet (London, England),
Sevda Erer, and Mehmet Zarifoglu
March 1995, The Annals of pharmacotherapy,
Sevda Erer, and Mehmet Zarifoglu
September 2002, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
Sevda Erer, and Mehmet Zarifoglu
December 1991, Clinical neuropharmacology,
Sevda Erer, and Mehmet Zarifoglu
January 1990, Revue neurologique,
Sevda Erer, and Mehmet Zarifoglu
January 1999, Neurologia i neurochirurgia polska,
Sevda Erer, and Mehmet Zarifoglu
January 2010, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Sevda Erer, and Mehmet Zarifoglu
September 2007, Revue neurologique,
Sevda Erer, and Mehmet Zarifoglu
December 2013, Parkinsonism & related disorders,
Copied contents to your clipboard!